{"count": 4, "results": [{"_id": "34611148", "pmid": 34611148, "pmcid": "PMC8492731", "title": "Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer", "journal": "NPJ Breast Cancer", "authors": ["Yee D", "Isaacs C", "Wolf DM", "Yau C", "Haluska P", "Giridhar KV", "Forero-Torres A", "Jo Chien A", "Wallace AM", "Pusztai L", "Albain KS", "Ellis ED", "Beckwith H", "Haley BB", "Elias AD", "Boughey JC", "Kemmer K", "Yung RL", "Pohlmann PR", "Tripathy D", "Clark AS", "Han HS", "Nanda R", "Khan QJ", "Edmiston KK", "Petricoin EF", "Stringer-Reasor E", "Falkson CI", "Majure M", "Mukhtar RA", "Helsten TL", "Moulder SL", "Robinson PA", "Wulfkuhle JD", "Brown-Swigart L", "Buxton M", "Clennell JL", "Paoloni M", "Sanil A", "Berry S", "Asare SM", "Wilson A", "Hirst GL", "Singhrao R", "Asare AL", "Matthews JB", "Hylton NM", "DeMichele A", "Melisko M", "Perlmutter J", "Rugo HS", "Fraser Symmans W", "Van't Veer LJ", "Berry DA", "Esserman LJ"], "date": "2021-10-05T00:00:00Z", "doi": "10.1038/s41523-021-00337-2", "meta_date_publication": "2021 Oct 5", "meta_volume": "7", "meta_issue": "1", "meta_pages": "131", "score": 50264.215, "text_hl": "@CHEMICAL_ganitumab @CHEMICAL_MESH:C545764 @@@Ganitumab@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ plus standard neoadjuvant therapy in @<m>DISEASE_Encephalitis_Herpes_Simplex</m> @DISEASE_MESH:D020803 @@@stage 2/3@@@ @DISEASE_Breast_Neoplasms @DISEASE_MESH:D001943 @@@breast cancer@@@", "citations": {"NLM": "Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer NPJ Breast Cancer. 2021 Oct 5;7(1):131. PMID: 34611148", "BibTeX": "@article{34611148, title={Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer}, author={Yee D and Isaacs C and Wolf DM and Yau C and Haluska P and Giridhar KV and Forero-Torres A and Jo Chien A and Wallace AM and Pusztai L and Albain KS and Ellis ED and Beckwith H and Haley BB and Elias AD and Boughey JC and Kemmer K and Yung RL and Pohlmann PR and Tripathy D and Clark AS and Han HS and Nanda R and Khan QJ and Edmiston KK and Petricoin EF and Stringer-Reasor E and Falkson CI and Majure M and Mukhtar RA and Helsten TL and Moulder SL and Robinson PA and Wulfkuhle JD and Brown-Swigart L and Buxton M and Clennell JL and Paoloni M and Sanil A and Berry S and Asare SM and Wilson A and Hirst GL and Singhrao R and Asare AL and Matthews JB and Hylton NM and DeMichele A and Melisko M and Perlmutter J and Rugo HS and Fraser Symmans W and Van't Veer LJ and Berry DA and Esserman LJ}, journal={NPJ Breast Cancer}, volume={7}, number={1}, pages={131}}"}}, {"_id": "35862706", "pmid": 35862706, "title": "Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy-d-Glucose with Metformin.", "journal": "J Virol", "authors": ["Berber E", "Rouse BT"], "date": "2022-07-27T00:00:00Z", "doi": "10.1128/jvi.00688-22", "meta_date_publication": "2022 Jul 27", "meta_volume": "96", "meta_issue": "14", "meta_pages": "e0068822", "score": 50250.883, "text_hl": "It showed that two drugs, @CHEMICAL_Deoxyglucose @CHEMICAL_MESH:D003847 @@@2-deoxy-d-glucose@@@ (@CHEMICAL_Deoxyglucose @CHEMICAL_MESH:D003847 @@@2DG@@@) and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, effectively diminished @DISEASE_Eye_Infections_Fungal @DISEASE_MESH:D015821 @@@ocular lesion@@@ expression, but only @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ avoided the complication of HSV spreading to the central nervous system (CNS) and causing @<m>DISEASE_Encephalitis_Herpes_Simplex</m> @DISEASE_MESH:D020803 @@@herpetic encephalitis@@@. ", "citations": {"NLM": "Berber E, Rouse BT. Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy-d-Glucose with Metformin. J Virol. 2022 Jul 27;96(14):e0068822. PMID: 35862706", "BibTeX": "@article{35862706, title={Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy-d-Glucose with Metformin.}, author={Berber E and Rouse BT}, journal={J Virol}, volume={96}, number={14}, pages={e0068822}}"}}, {"_id": "28769124", "pmid": 28769124, "pmcid": "PMC5541071", "title": "Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency", "journal": "Sci Rep", "authors": ["Chang MY", "Ma TL", "Hung CC", "Tian YC", "Chen YC", "Yang CW", "Cheng YC"], "date": "2017-08-02T00:00:00Z", "doi": "10.1038/s41598-017-07300-x", "meta_date_publication": "2017 Aug 2", "meta_volume": "7", "meta_issue": "1", "meta_pages": "7161", "score": 50073.965, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Inhibits Cyst Formation in a @SPECIES_7955 @@@Zebrafish@@@ Model of @<m>DISEASE_Encephalitis_Herpes_Simplex</m> @DISEASE_MESH:D020803 @@@Polycystin-2 Deficiency@@@", "citations": {"NLM": "Chang MY, Ma TL, Hung CC, Tian YC, Chen YC, Yang CW, Cheng YC. Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency Sci Rep. 2017 Aug 2;7(1):7161. PMID: 28769124", "BibTeX": "@article{28769124, title={Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency}, author={Chang MY and Ma TL and Hung CC and Tian YC and Chen YC and Yang CW and Cheng YC}, journal={Sci Rep}, volume={7}, number={1}, pages={7161}}"}}, {"_id": "20580422", "pmid": 20580422, "title": "Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.", "journal": "Lancet", "authors": ["Bergenstal RM", "Wysham C", "Macconell L", "Malloy J", "Walsh B", "Yan P", "Wilhelm K", "Malone J", "Porter LE", "DURATION-2 Study Group"], "date": "2010-08-07T00:00:00Z", "doi": "10.1016/S0140-6736(10)60590-9", "meta_date_publication": "2010 Aug 7", "meta_volume": "376", "meta_issue": "9739", "meta_pages": "431-9", "score": 50049.395, "text_hl": "Efficacy and safety of @CHEMICAL_Exenatide @CHEMICAL_MESH:D000077270 @@@exenatide@@@ once weekly versus @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@ or @CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@ as an adjunct to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ for treatment of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ (@<m>DISEASE_Encephalitis_Herpes_Simplex</m> @DISEASE_MESH:D020803 @@@DURATION-2@@@): a randomised trial.", "citations": {"NLM": "Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010 Aug 7;376(9739):431-9. PMID: 20580422", "BibTeX": "@article{20580422, title={Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.}, author={Bergenstal RM and Wysham C and Macconell L and Malloy J and Walsh B and Yan P and Wilhelm K and Malone J and Porter LE and DURATION-2 Study Group}, journal={Lancet}, volume={376}, number={9739}, pages={431-9}}"}}]}